Baxalta Inks $1.6B Cancer Drug Option Deal
Global pharmaceutical company Baxalta and a Danish biotech firm on Monday announced plans to co-develop six cancer drugs in a deal that could be worth as much as $1.6 billion, plus...To view the full article, register now.
Already a subscriber? Click here to view full article